Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data

[1] Brown TJ(2019)Chemotherapy-induced peripheral neuropathy JAMA Oncol 5 750-641

[2] Sedhom R(2017)Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review Front Pharmacol 8 86-2470

[3] Gupta A(2018)Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort J Neurol Neurosurg Psychiatry 89 636-5123

[4] Kerckhove N(2014)Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis Pain 155 2461-866

[5] Collin A(2020)Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy Cancer Med 9 5114-2612

[6] Condé S(2020)Long-term prevalence of sensory chemotherapy-induced peripheral neuropathy for 5 years after adjuvant FOLFOX chemotherapy to treat colorectal cancer: a multicenter cross-sectional study J Clin Med 9 2400-463

[7] Chaleteix C(2016)The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling JAMA Neurol 73 860-200

[8] Pezet D(2017)Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy J Clin Oncol 35 2604-3348

[9] Balayssac D(2018)Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: a longitudinal study Gynecol Oncol 149 455-2772

[10] Shah A(2021)The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients J Cancer Surviv 15 190-3493

[1] Brown TJ(2019)Chemotherapy-induced peripheral neuropathy JAMA Oncol 5 750-641

[2] Sedhom R(2017)Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review Front Pharmacol 8 86-2470

[3] Gupta A(2018)Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort J Neurol Neurosurg Psychiatry 89 636-5123

[4] Kerckhove N(2014)Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis Pain 155 2461-866

[5] Collin A(2020)Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy Cancer Med 9 5114-2612

[6] Condé S(2020)Long-term prevalence of sensory chemotherapy-induced peripheral neuropathy for 5 years after adjuvant FOLFOX chemotherapy to treat colorectal cancer: a multicenter cross-sectional study J Clin Med 9 2400-463

[7] Chaleteix C(2016)The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling JAMA Neurol 73 860-200

[8] Pezet D(2017)Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy J Clin Oncol 35 2604-3348

[9] Balayssac D(2018)Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: a longitudinal study Gynecol Oncol 149 455-2772

[10] Shah A(2021)The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients J Cancer Surviv 15 190-3493